N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)benzamide

Catalog No. :
ACGIEK663
CAS No. :
2096336-47-7
Molecular Formula :
C18H21BN2O3
Molecular Weight :
324.19

IUPAC Name:N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)benzamide

N-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)benzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)benzamide
IUPAC NameN-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)benzamide
Molecular FormulaC18H21BN2O3
Molecular Weight324.19
SMILESO=C(NC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1)C3=CC=CC=C3
InChI KeyDLFRCALNIJJLII-UHFFFAOYSA-N
SynonymBenzamide, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]-;N-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]benzamide
CAS No.2096336-47-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACGIEK663 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGIEK663 route product structure diagram
    ACGIEK6632096336-47-7
Inquiry

2. ACGIEK663 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMAPG390 route compound structure diagram
    ACMAPG3901195995-72-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACGIEK663 route product structure diagram
    ACGIEK6632096336-47-7
Inquiry

Comments (0)